Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Revolution Medicines, a clinical-stage oncology firm focusing on targeted therapies for RAS-addicted cancers, announced that CEO Mark A. Goldsmith will present at the 41st Annual J.P. Morgan Healthcare Conference from January 9-12, 2023, in San Francisco. Goldsmith's presentation is scheduled for January 10 at 11:15 a.m. Pacific in the Georgian Room of the Westin St. Francis Hotel. Live access to the presentation will be available on the company's website, and a replay will be accessible for at least 14 days post-conference.

REDWOOD CITY, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 41^st Annual J.P. Morgan Healthcare Conference. The conference will take place January 9-12, 2023, in San Francisco, California.

Details of the company’s presentation are as follows:

• 41^st Annual J.P. Morgan Healthcare Conference
  Conference Dates: January 9-12, 2023
  Presentation Date/Time: Tuesday, January 10, 2023, at 11:15 a.m. Pacific
  Location: Georgian Room of the Westin St. Francis Hotel

To access the live webcast of the presentation, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations. Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitors RMC-6236 (RAS^MULTI) and RMC-6291(KRAS^G12C) are currently in clinical development. Additional RAS(ON) Inhibitors in the company’s pipeline include RMC-9805 (KRAS^G12D), currently in IND-enabling development, RMC-8839 (KRAS^G13C), and additional compounds targeting other RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

FAQ

What is Revolution Medicines presenting at the J.P. Morgan Healthcare Conference?

Revolution Medicines will present targeted therapies for RAS-addicted cancers on January 10, 2023.

When is the 41st Annual J.P. Morgan Healthcare Conference?

The conference takes place from January 9-12, 2023.

Where can I access the live webcast of Revolution Medicines' presentation?

The live webcast can be accessed on the 'Events & Presentations' page of Revolution Medicines' website.

What is the schedule for Revolution Medicines' CEO presentation?

Mark A. Goldsmith will present on January 10, 2023, at 11:15 a.m. Pacific time.

How long will the webcast replay of the presentation be available?

The replay will be available for at least 14 days following the conference.